Bristol-Myers Squibb Company (BMY)
Return on total capital
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) | US$ in thousands | 10,685,000 | -6,432,000 | 9,606,000 | 8,945,000 | 9,432,000 |
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 18,473,000 | 16,335,000 | 29,430,000 | 31,061,000 | 35,946,000 |
| Return on total capital | 57.84% | -39.38% | 32.64% | 28.80% | 26.24% |
December 31, 2025 calculation
Return on total capital = EBIT ÷ (Long-term debt + Total stockholders’ equity)
= $10,685,000K ÷ ($—K + $18,473,000K)
= 57.84%
Peer comparison
Dec 31, 2025
Company name
Symbol
Return on total capital
Bristol-Myers Squibb Company
BMY
57.84%
AbbVie Inc
ABBV
—
Amgen Inc
AMGN
135.75%
Biogen Inc
BIIB
11.86%
Eli Lilly and Company
LLY
99.39%
Gilead Sciences Inc
GILD
—
Johnson & Johnson
JNJ
39.96%
Merck & Company Inc
MRK
40.59%
Organon & Co
OGN
141.83%
Pfizer Inc
PFE
10.95%